Sugi Predict

Sugi Predict / Compounds / SCHEMBL3489554

SCHEMBL3489554

SCHEMBL3489554

NC[C@H](O)c1cccc(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PNMT P11086 2/20 0.56
▸ BLM P54132 4/20 0.50
▸ MAPT P10636 3/20 0.50
▸ RECQL P46063 3/20 0.50
▸ TDP1 Q9NUW8 3/20 0.50
▸ TAAR1 Q96RJ0 3/20 0.50
▸ KDM4E B2RXH2 3/20 0.50
▸ HPGD P15428 2/20 0.50
▸ APEX1 P27695 2/20 0.50
▸ ADRB2 P07550 2/20 0.50
▸ ADRB1 P08588 2/20 0.50
▸ ADRB3 P13945 2/20 0.50
▸ LMNA P02545 2/20 0.50
▸ MAPK1 P28482 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ ADRA2A P08913 1/20 0.50
▸ ADORA3 P0DMS8 1/20 0.50
▸ DRD2 P14416 1/20 0.50
▸ ADRA2B P18089 1/20 0.50
▸ ADRA2C P18825 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL768162 1.00 PNMT (0.56) PNMTBLMMAPTRECQLTDP1
SCHEMBL31419997 1.00 PNMT (0.56) PNMTBLMMAPTRECQLTDP1
SCHEMBL768007 1.00 PNMT (0.56) PNMTBLMMAPTRECQLTDP1
Hydrochloric Acid SCHEMBL4465387 0.98 PNMT (0.54) PNMTBLMMAPTRECQLTDP1
Hydrochloric Acid SCHEMBL2327859 0.98 PNMT (0.54) PNMTBLMMAPTRECQLTDP1
Hydrochloric Acid SCHEMBL4802312 0.98 PNMT (0.54) PNMTBLMMAPTRECQLTDP1
Hydrochloric Acid SCHEMBL31332749 0.98 PNMT (0.54) PNMTBLMMAPTRECQLTDP1
Bicarbonate SCHEMBL9515153 0.93 KDM4E (0.51) PNMTBLMMAPTRECQLTDP1
SCHEMBL10318241 0.85 ADRB2 (0.44) PNMTTAAR1ADRB2ADRB1ADRB3
SCHEMBL1154749 0.83 ADRB3 (0.49) ADRB2ADRB1ADRB3LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109734712-B Aryl or heteroaryl substituted pyrrolidine amide derivatives and uses thereof 广东东阳光药业有限公司 2020-10-20 — — CN disclosed
US-10660888-B2 Aminoheteroaryl benzamides as kinase inhibitors NOVARTIS AG (CH) 2020-05-26 — — US disclosed
US-10660888-B2 Aminoheteroaryl benzamides as kinase inhibitors NOVARTIS AG (CH) 2020-05-26 — — US disclosed
CN-109776373-B Amide-substituted pyrrolidine amide derivatives and uses thereof 广东东阳光药业有限公司 2020-04-21 — — CN disclosed
US-20190247392-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-08-15 — — US disclosed
US-20190247392-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2019-08-15 — — US disclosed
CN-109776373-A The pyrrolidine derivative and application thereof that amide replaces 广东东阳光药业有限公司 2019-05-21 — — CN disclosed
CN-109734712-A The pyrrolidine derivative and application thereof that aryl or heteroaryl replace 广东东阳光药业有限公司 2019-05-10 — — CN disclosed
US-10188649-B2 Aminoheteroaryl benzamides as kinase inhibitors NOVARTIS AG (CH) 2019-01-29 — — US disclosed
US-10188649-B2 Aminoheteroaryl benzamides as kinase inhibitors NOVARTIS AG (CH) 2019-01-29 — — US disclosed
EP-0627397-A1 Optically active 1-phenyl-2-substituted propane derivatives and methods of producing the same DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 1994-12-07 — — EP disclosed
CN-1084846-A Ethanolamine derivant FUJISAWA PHARMACEUTICAL CO (JP) 1994-04-06 — — CN disclosed
EP-0583485-A1 ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES. FUJISAWA PHARMACEUTICAL CO (JP) 1994-02-23 — — EP disclosed
WO-1993015041-A1 ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-08-05 — — WO disclosed
EP-0294995-B1 OXAZOLIDIN-2-ONE DERIVATIVES AS HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1992-11-11 — — EP disclosed
US-4968707-A ANTIDIABETIC AGENTS PFIZER INC. (US) 1990-11-06 — — US disclosed
EP-0303546-A2 O-alkylation process for N-(hydroxy)aralkyl phenyl ethanol amines SANOFI (FR) 1989-02-15 — — EP disclosed
EP-0303545-A2 Process for the preparation of phenylethanolaminotetralines ELF SANOFI (FR) 1989-02-15 — — EP disclosed
WO-1988009661-A1 OXAZOLIDIN-2-ONE DERIVATIVES AS HYPOGLYCEMIC AGENTS PFIZER INC. (US) 1988-12-15 — — WO disclosed
EP-0294995-A1 Oxazolidin-2-one derivatives as hypoglycemic agents PFIZER INC. (US) 1988-12-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190247392-A1 AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS ABL1, MAP3K12, MAP3K2 PNMT 1476/4885BLM 4142/4885MAPT 1600/4885
US-10188649-B2 Aminoheteroaryl benzamides as kinase inhibitors ABL1, MAP3K12, MAP3K2 PNMT 1476/4885BLM 4142/4885MAPT 1600/4885
US-10660888-B2 Aminoheteroaryl benzamides as kinase inhibitors ABL1, MAP3K12, MAP3K2 PNMT 1476/4885BLM 4142/4885MAPT 1600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.